Gold Nanorods as Drug Delivery Vehicles for Rifampicin Greatly Improve the Efficacy of Combating Mycobacterium tuberculosis with Good Biocompatibility with the Host Cells

• Published in: Bioconjugate chemistry Vol. 27; no. 10; pp. 2486 - 2492
• Main Authors: Ali, Hala R, Ali, Moustafa R. K, Wu, Yue, Selim, Salah A, Abdelaal, Hazem F. M, Nasr, Essam A, El-Sayed, Mostafa A
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 19-10-2016
• Subjects: Animals; Antibiotics; Antitubercular Agents - administration & dosage; Antitubercular Agents - pharmacokinetics; Cell Line; Cells; Drug Delivery Systems - methods; Drug Liberation; Gold; Gold - chemistry; Host-Pathogen Interactions - drug effects; Macrophages - drug effects; Macrophages - microbiology; Mice; Mycobacterium tuberculosis; Mycobacterium tuberculosis - drug effects; Mycobacterium tuberculosis - pathogenicity; Nanomaterials; Nanotubes - chemistry; Rifampin - administration & dosage; Toxicity; Tuberculosis; Tuberculosis - drug therapy; Tuberculosis - microbiology
• ISSN: 1043-1802; 1520-4812
• DOI: 10.1021/acs.bioconjchem.6b00430

TB remains a challenging disease to control worldwide. Nanoparticles have been used as drug carriers to deliver high concentrations of antibiotics directly to the site of infection, reducing the duration of treatment along with any side effects of off-target toxicities after systemic exposure to the antibiotics. Herein we have developed a drug delivery platform where gold nanorods (AuNRs) are conjugated to rifampicin (RF), which is released after uptake into macrophage cells (RAW264.7). Due to the nature of the macrophage cells, the nanoparticles are actively internalized into macrophages and release RF after uptake, under the safety frame of the host cells (macrophage). AuNRs without RF conjugation exhibit obvious antimicrobial activity. Therefore, AuNRs could be a promising antimycobacterial agent and an effective delivery vehicle for the antituberculosis drug Rifampicin for use in tuberculosis therapy.